CoChat

Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers

Open access
Mugarza, Edurne, van Maldegem, Febe, Boumelha, Jesse, Moore, Christopher, Rana, Sareena, Llorian Sopena, Miriam, East, Philip, Ambler, Rachel, Anastasiou, Panayiotis, Romero-Clavijo, Pablo, Valand, Karishma, Cole, Megan, Molina-Arcas, Miriam, Downward, Julian · 2022 · Science Advances

Published version of a preprint

Cited by 142

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Recently developed KRAS G12C inhibitory drugs are beneficial to lung cancer patients harboring KRAS G12C mutations, but drug resistance frequently develops. Because of the immunosuppressive nature of the signaling network controlled by oncogenic KRAS, these drugs can indirectly affect antitumor immunity, providing a rationale for their combination with immune checkpoint blockade. In this study, we have characterized how KRAS G12C inhibition reverses immunosuppression driven by oncogenic KRAS in a number of preclinical lung cancer models with varying levels of immunogenicity. Mechanistically, KRAS G12C inhibition up-regulates interferon signaling via Myc inhibition, leading to reduced tumor infiltration by immunosuppressive cells, enhanced infiltration and activation of cytotoxic T cells, and increased antigen presentation. However, the combination of KRAS G12C inhibitors with immune checkpoint blockade only provides synergistic benefit in the most immunogenic tumor model. KRAS G12C inhibition fails to sensitize cold tumors to immunotherapy, with implications for the design of clinical trials combining KRAS G12C inhibitors with anti-PD1 drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.abm8780

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 27

  1. 10.3322/caac.21492 · DOI · Paper page
  2. 10.3322/caac.21590 · DOI · Paper page
  3. 10.1038/nm.2697 · DOI · Paper page
  4. 10.3390/cancers13010151 · DOI · Paper page
  5. 10.1126/science.aaa1348 · DOI · Paper page
  6. 10.1158/1078-0432.CCR-18-3904 · DOI · Paper page
  7. 10.1084/jem.20201414 · DOI · Paper page
  8. 10.1038/s41467-021-26214-x · DOI · Paper page
  9. J. Boumelha S. de Carné Trécesson E. K. Law P. Romero-Clavijo M. A. Coelho K. Ng E. Mugarza C. Moore S. Rana D. R. Caswell M. Murillo D. C. Hancock P. P. Argyris W. L. Brown C. Durfee L. K. Larson R. I. Vogel A. Suárez-Bonnet S. L. Priestnall P. East S. J. Ross G. Kassiotis M. Molina-Arcas C. Swanton R. Harris J. Downward An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations. bioRxiv 2020.12.22.423126 [Preprint]. 17 January 2022. https://doi.org/10.1101/2020.12.22.423126. · doi:10.1101/2020.12.22.423126
  10. 10.1073/pnas.2025570118 · DOI
  11. 10.3390/genes12060899 · DOI · Paper page
  12. 10.1038/sj.onc.1209237 · DOI · Paper page
  13. 10.1038/s41467-020-19288-6 · DOI · Paper page
  14. 10.1016/S1470-2045(16)00078-4 · DOI · Paper page
  15. 10.1016/j.ccell.2016.04.014 · DOI · Paper page
  16. Y. Zhu, W. G. Hawkins, D. G. DeNardo, Regramming myeloid responses to improve cancer immunotherapy. Onco. Targets Ther. 4, e974399 (2015).
  17. 10.1158/2159-8290.CD-19-1409 · DOI · Paper page
  18. 10.1158/1078-0432.CCR-19-3524 · DOI
  19. B. Seliger, C. Harders, U. Wollscheid, M. S. Staege, A. B. Reske-Kunz, C. Huber, Suppression of MHC class I antigens in oncogenic transformants: Association with decreased recognition by cytotoxic T lymphocytes. Exp. Hematol. 24, 1275–1279 (1996).
  20. 10.1002/ijc.11681 · DOI · Paper page
  21. 10.1038/s41573-018-0007-y · DOI · Paper page
  22. 10.1038/nrc.2017.17 · DOI · Paper page
  23. 10.1126/scitranslmed.aaa4691 · DOI · Paper page
  24. 10.1158/1078-0432.CCR-15-1125 · DOI · Paper page
  25. 10.1007/s11912-016-0531-z · DOI
  26. 10.1038/s41591-019-0476-5 · DOI · Paper page
  27. 10.1158/0008-5472.CAN-19-3038 · DOI · Paper page

Cited by

Metadata

Authors
Mugarza, E., van Maldegem, F., Boumelha, J., Moore, C., Rana, S., Llorian Sopena, M., East, P., Ambler, R., Anastasiou, P., Romero-Clavijo, P., Valand, K., Cole, M., Molina-Arcas, M., & Downward, J.
Venue
Science Advances
Published
2022-07-22
Volume
8
Issue
29
Pages
eabm8780-eabm8780
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4285987606
Cited by
142
References
26
FWCI
10.51
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.